Yahoo Finance report covering Health In Tech Inc. (Class A) (HIT) market action, institutional positioning, and fundamental catalysts.
Why HIT Stock advanced +1.30% Today — RQD Quant Desk Flash
Health In Tech Inc. (Class A) (HIT) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is HIT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Health In Tech Inc. (Class A) (NASDAQ: HIT) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $0.58 (+1.30% 1D, market cap $37.7M). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 15/20. Across 1097 tracked Financials issuers, HIT ranks #517 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does HIT compare to HUIZ and SLQT in the Financials sector?
▼
Within the Financials sector (Specialty Insurers), HIT carries a Roarable D+ (56/100 RQD), trailing P/E of 31.2x, gross margin of —, and ROIC of 7.5%. By comparison, HUIZ (Huize Holding Limited) holds a B- grade (70/100 RQD, P/E 39.0x, ROIC 3.1%, cap $22.7M) and SLQT (SelectQuote Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC 7.4%, cap $64.0M). Among the 5-stock peer group, HIT leads on earnings multiple (31.2x) while EHTH leads on capital efficiency (8.3% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for HIT?
▼
Per HIT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002019505), Health In Tech Inc. (Class A) generated $33.3M in revenue (+71.0% YoY), $1.3M in net income, and $3.1M in free cash flow against $23.1M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 9.4% FCF Margin ($3.1M FCF) & 52% Gross Margin
SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
⚔️ Adversarial Opposing Case: Why the HIT Bull Thesis Could Fail
Even with a 56/100 (D+) score, HIT faces multiple-compression risk if 31.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($0.79) or 200D SMA ($1.14) invalidates the momentum regime and cuts Target Base ($0.57) toward Bear Floor ($0.44).
Why HIT Stock advanced +1.30% Today — RQD Quant Desk Flash
Health In Tech Inc. (Class A) (HIT) advanced +1.30% to $0.58, trading at 3% of its 52-week range ($0.5 – $3.11). Stretched risk/reward at 31x P/E (8% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($0.5 – $3.11) with RSI-14 at 38.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.58 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $3.1M annual free cash flow.
Stock Titan report covering Health In Tech Inc. (Class A) (HIT) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering Health In Tech Inc. (Class A) (HIT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Health In Tech Inc. (Class A) (HIT) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Health In Tech Inc. (Class A) (HIT) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Health In Tech Inc. (Class A) (HIT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Health In Tech Inc. (Class A) (HIT) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Health In Tech Inc. (Class A) (HIT) market action, institutional positioning, and fundamental catalysts.
Health In Tech, Inc. (Nasdaq: HIT), an AI-enabled InsurTech platform company, today announced that it will release financial results for the third quarter ended September 30, 2026, following the close of market on Thursd
Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or the "Company"), an AI-enabled InsurTech platform company transforming the health insurance marketplace through technology, automation and innovation, today announce
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HIT)
- ✓Walkthrough of HIT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
HIT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +71.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HIT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HIT. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HIT)
1. Head-to-Head Financials Peer Comparison (HIT vs. HUIZ, SLQT, CCG, EHTH)
Industry: Specialty Insurers (33 Tracked Issuers)Across 1097 tracked Financials securities in the Roarable RQD universe, Health In Tech Inc. (Class A) (HIT) ranks #517 by composite RQD confidence (56/100, grade D+) and #1027 by equity capitalization ($37.7M). Within this direct 5-issuer industry benchmark cohort, HIT leads on earnings valuation at 31.2x trailing P/E, while EHTH leads on capital efficiency and profitability with 8.3% ROIC and — gross margin. HUIZ currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with HIT at 56/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HIT
ACTIVE
Health In Tech Inc. (Class A) | D+ | 56/100 | 31.2x | — | 7.5% | +1.30% | $37.7M | Benchmark Subject |
| HUIZ Huize Holding Limited | B- | 70/100 | 39.0x | — | 3.1% | -3.11% | $22.7M | /huiz-vs-hit → |
| SLQT SelectQuote Inc. | D- | 39/100 | — | — | 7.4% | +12.61% | $64.0M | /slqt-vs-hit → |
| CCG Cheche Group Inc. (Class A) | D+ | 55/100 | — | — | — | +0.28% | $17.9M | /ccg-vs-hit → |
| EHTH eHealth Inc. | D- | 41/100 | — | — | 8.3% | +2.60% | $15.8M | /ehth-vs-hit → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002019505 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Health In Tech Inc. (Class A) (HIT) reported GAAP revenue of $33.3M (+71.0% vs. FY2024 revenue of $19.5M , and +74.0% cumulative change since FY2023) , GAAP net income of $1.3M, operating cash flow of $3.1M, and free cash flow of $3.1M (+44.0% YoY). On the balance sheet, HIT closed FY2025 with $23.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $33.3M | $1.3M | $3.1M | $3.1M | $23.1M | — |
| FY2024 (FY) | 2024-12-31 | $19.5M | $670.5K | $2.2M | $2.2M | $15.8M | — |
| FY2023 (FY) | 2023-12-31 | $19.2M | $0 | $1.5M | $1.5M | — | — |
3. HIT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs HIT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Health In Tech Inc. (Class A) (NASDAQ: HIT) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $0.58 (+1.30% 1D, market cap $37.7M). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 15/20. Across 1097 tracked Financials issuers, HIT ranks #517 in composite RQD confidence.
How does HIT compare to HUIZ and SLQT in the Financials sector?
Within the Financials sector (Specialty Insurers), HIT carries a Roarable D+ (56/100 RQD), trailing P/E of 31.2x, gross margin of —, and ROIC of 7.5%. By comparison, HUIZ (Huize Holding Limited) holds a B- grade (70/100 RQD, P/E 39.0x, ROIC 3.1%, cap $22.7M) and SLQT (SelectQuote Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC 7.4%, cap $64.0M). Among the 5-stock peer group, HIT leads on earnings multiple (31.2x) while EHTH leads on capital efficiency (8.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for HIT?
Per HIT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002019505), Health In Tech Inc. (Class A) generated $33.3M in revenue (+71.0% YoY), $1.3M in net income, and $3.1M in free cash flow against $23.1M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Where is HIT trading relative to its 50-day, 200-day, and 52-week technical levels?
HIT last traded at $0.58 (+1.30% on volume of 70,120 shares), positioning the stock -26.58% below its 50-day simple moving average ($0.79) and -49.12% below its 200-day simple moving average ($1.14). Across its 52-week range of $0.50 to $3.11, HIT sits at the 3.1% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.65).
HIT — Health In Tech Inc. (Class A): What the Facts Mean to a Prospective Investor
1. Roarable Rating Brief: What This Means to a Prospective Investor
Health In Tech Inc. (Class A) (HIT) earns a live Roarable RQD composite score of 56/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $0.58 (+1.30% 1D, market capitalization $37.7M).
- Fundamental Cash Engine (15/20): Anchored by return on invested capital (ROIC) of 7.5%, gross margin of —, operating margin of —, and free cash flow yield of 7.85%.
- Whale 13F & Options Flow (6/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 7/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Health In Tech Inc. (Class A) is a NASDAQ-listed issuer classified under the Financials sector and the Specialty Insurers industry..0B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Health In Tech Inc. (Class A) (HIT) reported $33.3M in annual revenue (up from $19.5M in FY2024, +71.0% YoY) and $1.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($19.2M revenue, $0 net income) through FY2025, HIT scaled operating cash flow to $3.1M and free cash flow to $3.1M, backed by $23.1M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D+ • RQD 56/100): Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 15/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $0.50 – $3.11 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 31.2x trailing P/E against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Specialty Insurers (Financials), HIT carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can HIT sustain or expand its — operating margin and 7.5% ROIC against Specialty Insurers peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $33.3M and free cash flow of $3.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is HIT's 26.2x forward P/E multiple to Financials capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
HIT Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Health In Tech Inc. (Class A) (HIT) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Health In Tech Inc. (Class A) (HIT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Health In Tech Inc. (Class A) (HIT) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering Health In Tech Inc. (Class A) (HIT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Health In Tech Inc. (Class A) (HIT) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Health In Tech Inc. (Class A) (HIT) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Health In Tech Inc. (Class A) (HIT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Health In Tech Inc. (Class A) (HIT) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Health In Tech Inc. (Class A) (HIT) market action, institutional positioning, and fundamental catalysts.
HIT Bull vs. Bear Conversation Board — What's Your Call at $0.58?
Revenue grew from $19.2M in FY 2023 to $33.3M in FY 2025 while FCF rose to $3.1M, supporting a 7.85% FCF yield.
Revenue grew from $19.2M in FY 2023 to $33.3M in FY 2025 while FCF rose to $3.1M, supporting a 7.85% FCF yield.. When you look under the hood at HIT, Fundamental Cash Engine is 15/20 with 0.0% gross margins and 7.5% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (6/20) has been quietly accumulating below $3.11. My 12M target is $0.70.
Both sides have a point here — HIT's 12/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
The RQD verdict is a Roarable Sell with a score of 56, weighed down by weak institutional flow and a Beta of 1.0 macro fit.
Here is the bear case nobody on the bull side wants to address on HIT: The RQD verdict is a Roarable Sell with a score of 56, weighed down by weak institutional flow and a Beta of 1.0 macro fit.. At 31.2x trailing P/E, even a small guidance miss in Specialty Insurers triggers a 12-15% air pocket.